Monrovia, CA, United States
Monrovia, CA, United States

Time filter

Source Type

Patent
Xencor | Date: 2016-06-17

The present invention is directed to novel heterodimeric antibodies.


Patent
Xencor | Date: 2016-06-17

The present invention is directed to novel heterodimeric antibodies.


Immunoglobulin compositions that simultaneously co-engage antigens, where one of the antigens is bound bivalently and the other antigen is bound monovalently. The novel immunoglobulins described preferably utilize heterodimeric Fc regions.


Patent
Xencor | Date: 2017-03-08

The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.


The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.


Patent
Xencor | Date: 2015-06-15

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level that achieves a total exposure to said patient measured by area under the curve (AUG) of 14,500 ug*day/ml or more.


Patent
Allergan, Inc. and Xencor | Date: 2016-12-28

The present disclosure relates to antibodies and polynucleotides encoding the same, that may be used to prevent, control, or reduce the activity of the complement pathway. In addition, the disclosure is directed to compositions and methods for diagnosing and treating diseases mediated by or involving complement C5. Specifically, the disclosure is related to C5 antibodies.


Patent
Xencor | Date: 2017-01-13

The present invention relates to Fc variants with optimized Fc ligand binding properties, methods for their generation, Fc polypeptides comprising Fc variants with optimized Fc ligand binding properties, and methods for using same.


Patent
Xencor | Date: 2017-04-26

The present disclosure relates to the treatment of chronic lymphocytic leukemia. Monoclonal antibody XmAb5574 is efficacious when administered to patient at certain dosage regimens. Further disclosed are regimens including said antibody is administered at least once weekly over at least eight weeks; or/and said antibody is administered at a level that achieves a total exposure to said patient measured by area under the curve (AUG) of 14,500 ug *day/ml or more.


Patent
Xencor | Date: 2017-02-01

Heterodimeric proteins including heterodimeric antibodies that bind to CD38 and CD3.

Loading Xencor collaborators
Loading Xencor collaborators